Luye Pharma Launches Its Transdermal Patch Rotigotine Luye in the UK for the Treatment of Parkinson’s Disease and Restless Legs Syndrome
Shanghai, April 10, 2025 – Luye Pharma Group announced the recent launch of its rotigotine transdermal patch, Rotigotine Luye, in the UK. This product is indicated for the treatment of the signs and symptoms of early-stage and advanced idiopathic Parkinson's disease (PD) as well as ...
April 10,2025
Luye Pharma’s Class 1 Innovative Antidepressant Ruoxinlin® Approved for Marketing in Macao
Shanghai, April 7, 2025 - Luye Pharma Group today announced that Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), its innovative drug for treating Major Depressive Disorder (MDD), has been approved for marketing in Macao by the Pharmaceutical Administration ...
April 07,2025
07
2025-04
Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
31
2025-03
Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer’s Dementia
14
2025-01
Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.
03
2024-12
Luye Pharma Announces the Approval of Zepzelca® (Lurbinectedin for Injection) by China’s National Medical Products Administration for the Treatment of Small Cell Lung Cancer
28
2024-11
Luye Pharma’s Ruoxinlin and Other Drugs Included on China’s 2024 National Reimbursement Drug List
11
2024-11
Luye Pharma’s Class 1 Innovative Antidepressant Targeting NET/DAT/GABAAR Approved for Clinical Trials in China
29
2024-08
Luye Pharma Announces 2024 Half Year Results
13
2024-08
Luye Pharma’s mRNA-based Therapeutic HPV Vaccine LY01620 Approved for Clinical Trials in China
05
2024-08
Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China
28
2024-07
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder
